Search PubMed⌕ Search

Biomedical subjects

H Furue

Publications and source records attributed to H Furue.

At least 145 records · Page 8Linked to original sources
PubMed1982

[Clinical experiences with UFD-1].

FD-1, 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil, is an anticancer agent newly developed in Japan and is a kind of marked compound of 5-fluorouracil. FD-1 changes to 3-FT and tegafur and is then converted to 5-fluorouracil. From our clinical observations, FD-1 showed excellent clinical effects in a daily dose of 600 mg. However, in some instances toxicities of central nervous system were developed. On the other hand, there is evidence that uracil enhances antitumor activity of FD-1 in the treatment of sarcoma 180 bearing mice and AH130 bearing rats. On oral administration of FD-1 plus uracil in various combination ratios, the high T/B value (ratio of the concentration of 5-fluorouracil in the tumor and blood) is obtained at a ratio of uracil to tegafur of 20 to 50. Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1. However, no tumor regression was observed in any of our cases. On the contrary, toxic manifestations were experienced in five of fifteen cases. They mainly consisted of mild G.I. toxicities. Furthermore, in one case, ataxia developed. Our clinical studies revealed no usefulness of UFD-1 in the treatment of advanced adenocarcinoma cases.

Adult↗
PubMed1982

[Phase I study of a new anticancer agent CAM--results of cooperative study].

CAM is a derivative compound of mycophenolic acid produced by Penicillium brevicompactum, and is a new oral Purine antagonistic anticancer agent. The Phase I study was carried out cooperatively in ten hospitals. The results are as follows: The administration method was single administration and the starting dose was 200 mg/m2 (1n). The dose level was escalated according to varied Fibonacci formula. The number of total cases was thirty-one: three cases at 1n level, four at 2n, six at 3.3n, six at 7n and seven at 9n. Side effects were observed in five of thirteen cases over 7n dose levels, such as nausea, vomiting, anorexia and diarrhea. Leukopenia was developed in only one case at 7n dose level. Other side effects such as anemia, thrombocytopenia, and disturbances of liver function and renal function were not observed. It was estimated from above results that a dose limiting factor of CAM is nausea and vomiting. A subtoxic dose was 7n (1,400 mg/m2) and a maximum tolerated dose was 9n (1,800 mg/m2) which corresponded to 2,200-3,000 mg as a single administration.

Animals↗
PubMed1982

[TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers].

Tumor regression was observed in only one patient. Twelve (33%) of the 36 patients reported adverse effects: gastrointestinal symptoms in 8, CNS symptoms in 3, and others in 1. The antitumor efficacy of TAC-278 was insufficient while incidence of adverse effects was similar to other 5-FU derivatives in man and the clinical usefulness of the drug was hardly found. TAC-278 has been developed with an aim to give higher plasma concentrations of 5-FU in man. Even at a dose causing adverse effects, however, the clinical efficacy of TAC-278 was unsatisfactory. The study is a meaning tal eince the results suggest that there might be a more important factor than blood concentration of 5-FU to enhance an antitumor effect of 5-FU derivatives.

Adult↗
PubMed1982

[Phase I study of a new antitumor antibiotic, neothramycin].

Phase I study of a new antitumor antibiotic, neothramycin which belongs to anthramycins was performed by a cooperative study group involving 15 major institutions. A total of 63 cases including 42 various solid tumors and 21 hematologic tumors refractory to standard treatments underwent the study during June 1979 to June 1981. Doses of single injection were escalated from an initial dose of 2 mg/m2 estimated by one twentieth of LD10 in mice up to 60 mg/m2. The most frequent and severest toxicity was nausea and vomiting seen in about the half of patients being administered dosages ranged from 24 mg/m2 to 40 mg/m2, and 3 out of 4 patients received dosages exceeding 50 mg/m2 required clinical managements; moreover, 1 out of 2 patients administered 60 mg/m2 was ranked as grade 4 of the criterion of toxicities in WHO handbook. Other clinical toxicities such as skin rash, hepatotoxicity or nephrotoxicity observed in the minority of the patients were reversible. Furthermore, hematologic toxicity was extremely mild and appeared not to be dose dependent. One patient with chronic myelogeneous leukemia had a hematological improvement and the other with esophageal cancer had a partial response. The result indicates that a dose limiting factor of neothramycin is nausea and vomiting, and a maximum tolerated dose of a single injection is 60 mg/m2. A dose schedule of 30-40 mg/m2 appears to be an optimal dose for Phase II study.

Animals↗
PubMed1978

Clinical experiences with aclacinomycin-A.

Aclacinomycin is a new anthracycline analog of adriamycin and daunomycin. Aclacinomycin contains three sugars. The drug has been studied in 22 cases in a phase 1 type of trial on a schedule 20 mg i.v. every other day up to a total of 300 mg. Toxicity has consisted of myelosuppression, nausea and vomiting, and transient hepatic disturbances. Evidence of clinical activity was observed in several cases including a case of breast cancer and gastric cancer. Although no full patial remissions were recorded, further study is continuing.

Animals↗
PubMed1978

Clinical aspects of adriamycin in Japan.

Adriamycin has not been as extensively evaluated in Japan as in some other countries. This is due both to the widespread use of mitomycin C and importantly to the alopecia caused by adriamycin being particularly disturbing to Japanese patients. Japanese studies have shown the drug to be highly active in tumors such as stomach cancer (31/92), lung cancer (27/84), and malignant lymphomas (15/46). Combination studies have been mainly with 5-FU although others have also been investigated. Other approaches which have been studied include intraarterial infusion, local application in bladder cancer, intrapleural application and in the treatment of childhood malignancies.

Doxorubicin↗